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Background: Benefits of community-based whole-body vibration (WBV) as a mode of exercise training for people
with chronic obstructive pulmonary disease (COPD) have not been investigated. The low skill demand of WBV
may enhance habitual sustainability to physical activity by people with COPD, provided efficacy of WBV can be
established. The purpose of this trial was to compare a community-based WBV intervention with a sham WBV
(SWBV) intervention and monitor exacerbations, exercise tolerance, and functional performance of the lower limbs
of people with COPD.
Methods: Community-dwelling adults with a GOLD clinical diagnosis of COPD were recruited to the trial. This was a
Phase II efficacy trial with crossover to sham intervention interspersed with two-week washout. Each six-week
intervention consisted of two sessions per week of either WBV or SWBV. The interventions were completed in
the home of each participant under supervision. The outcome measures were selected psychological (perceived
dyspnoea) and physiological (heart rate and oxygen saturation) responses to exercise, simulated activities of daily living
(timed-up-and got test and 5-chair stands test), and selected kinematic variables of gait across the 14-week trial.
Results: Sixteen adults with stable COPD were recruited to the trial. No exacerbations were reported during the WBV
or SWBV interventions. After WBV, performance of activities of daily living (ADLs) and gait improved (p≤ 0.05), while
there was no change after SWBV (p > 0.05). Despite five withdrawals during the washout period, a 100% compliance to
each six-week intervention was noted.
Conclusions: Results showed that WBV did not exacerbate symptoms of COPD that can be associated with physical
inactivity. The WBV intervention improved tests to simulate ADLs such as rising from a chair, turning, and walking gait
with greater effect than a SWBV intervention. If a placebo effect was systemic to the WBV intervention, the effect was
negligible. As a standalone community-based intervention, WBV was an efficacious mode of exercise training for
people with stable COPD that did not negatively effect exercise tolerance or exacerbate the disease, while concurrently
improving functional performance of the lower limbs.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12612000508875.
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As a cornerstone of COPD management, a minimum
goal of pulmonary rehabilitation is the maintenance of
exercise tolerance and performance of activities of daily
living (ADLs) [1]. As components of pulmonary re-
habilitation, efficacy of modes of resistance training and
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reproduction in any medium, provided the orimprovement in exercise tolerance [2]. However, the
associated perceived dyspnoea and hypoxemia can limit
compliance to pulmonary rehabilitation interventions
[3] and as such, the need for safe and valid exercise
interventions specifically for people with COPD are
salient. For initiatives to assist the promotion of habit-
ual and sustainable exercise training and reduce the
burden of COPD, a strong evidence base supporting
program design is needed.
Two common modes of exercise training; aerobic con-
ditioning and resistance training, routinely exacerbatel Ltd. This is an Open Access article distributed under the terms of the Creative
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duced physical activity because of fear of breathlessness
[4]. The clinical and social merit of modes of exercise
training that can minimise dyspnoea may add to the
benefit of pulmonary rehabilitation interventions for
people with COPD.
Recently, effects of whole-body vibration (WBV) on
muscular strength and muscular power of the lower limbs
of people with COPD have been investigated [5,6]. Coupled
with pulmonary rehabilitation, WBV may have enhanced
exercise tolerance, and did not elicit exacerbations of the
disease [5]. As a standalone out-patient intervention, WBV
improved functional capacity of people with COPD [6].
However, efficacy of WBV as a standalone community-
based mode of exercise training attractive to individuals
after structured pulmonary rehabilitation and other modes
of out-patient care requires further investigation.
It remains unknown if a long-term community-based
WBV intervention would elicit exacerbations of COPD,
such as increased dyspnoea or hypoxemia, or if a WBV
intervention would be well tolerated and adhered to by
community-dwelling adults with stable COPD. As such,
the aim of this Phase II efficacy trial was to report long-
term benefits of a standalone community-based WBV
intervention on performance of ADLs and gait by people
with COPD as well as acute effects on dyspnoea, heart
rate, and oxygen saturation.
Methods
Design
This Phase II efficacy trial was competed with a non-
randomised, cross-over design to sham [7]. Participants
with COPD provided informed consent to be allocated
first to; (1) a six-week WBV intervention, and then (2) a
six-week sham WBV (SWBV) intervention. A two-week
washout interval interspersed the WBV and SWBV in-
terventions. Across the 14-week trial period, data were
collected at baseline and subsequent fortnights. Partici-
pants completed two training sessions per week. Partici-
pants agreed not to commence physical activity beyond
their usual routine across the 14-week duration of the trial.
The trial was approved by the Southern Health Human
Research Ethics Committee A and the Australian Catholic
University Human Research Ethics Committee. The trial is
registered with the Australian New Zealand Clinical Trials
Registry (ACTRN12612000508875).
Participants
Patients of the Department of Sleep and Respiratory
Medicine, Monash Medical Centre, with a GOLD diag-
nosis of COPD were contacted via introductory letter to
peruse interest in the trial. For inclusion to the trial, po-
tential participants had to exhibit stable COPD, be living
in a fully-independent residence, and have the capacityto complete ADLs [7,8]. Potential participants also had
to be free of self-reported WBV contraindications [9]
and successfully complete a battery of balance, vision and
cognition tests [8]. Potential participants were excluded if
they were currently treated with corticosteroids or had ex-
perienced self-reported COPD exacerbations earlier than
six months prior to the commencement of the trial.
Independent and dependent variables
The independent variables were ‘intervention’ with two
levels: (1) WBV and, (2) SWBV, and ‘test occasion’ with
three levels: (1) pre-test, (2) mid-test, and (3) post-test.
The dependent variables were: (1) acute exercise toler-
ance (rating of perceived dyspnoea, heart rate, and
oxygen saturation), and (2) long-term functional per-
formance (timed-up-and-go test, 5-chair stands test,
stride length, stride time, and stride velocity). Acute data
were collected prior to and during the final WBV or
SWBV bout [7,10]. Long-term data were collected at
least 48 hours after a WBV or SWBV bout [8,11].
Acute exercise tolerance was quantified with the Borg
CR-10 VAS assessment of perceived breathing limitation
[12]. Heart rate, oxygen saturation, and blood pressure
were also quantified, with the CARESCOPE™ V100 Vital
Sign Monitor (GE Health Care, Milwaukee, USA). Reli-
ability of the test procedures was no less than ‘acceptable’
(ICC ≥ 0.700) for the three dependent variables [10].
The timed-up-and-go test (TUG) and 5-chair stands
test (5-chair) were used to simulate ADLs and describe
long-term functional performance. Kinematic variables
of gait: stride length, stride time, and stride velocity were
quantified with a GAITRite® Electronic Walkway (CIR
Systems Inc, Peekskill, USA). With the methods de-
scribed in our study protocol [7], reliability of the test
procedures was no less than ‘good’ (ICC ≥ 0.881) for the
five dependent variables.
Interventions
The same side alternating vibration platform (Amazing
Super Health, Melbourne, AUS) was transported to the
homes of the participants for each training session. For
each WBV bout, the vibration platform frequency was
set at 25 Hz with a peak-to-peak displacement at 2.0
mm, peak acceleration was ~24.67 m.s−2, and the result-
ing gravitational force was ~2.52 g. Validity of the vibra-
tion platform peak-to-peak displacement and frequency
were established prior to commencement of the trial
[13]. A prototype vibration platform was developed to
deliver the SWBV intervention. For each SWBV bout,
the vibration platform frequency was 25 Hz and peak-
to-peak displacement was ~0.0 mm, peak acceleration
was ~0.00 m.s−2, gravitational force was ~0.0 g (cogni-
sant that the Earth’s gravitational force is constant 1.0 g).
When the prototype vibration platform was operational,
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have felt vibration. Participants were told the SWBV
intervention was an “ultra-low frequency” vibration inter-
vention that is “very different” to the WBV intervention.
The participant wore flat soled shoes. Skidding was
checked according to the recommended method of the
International Society of Musculoskeletal and Neuronal In-
teractions [14]. Participants were told to stand with a bent
knee posture that could be maintained for the duration of
each WBV and SWBV bout. Knee flexion was checked
manually with a goniometer after 30 seconds of every
bout. During WBV, the participants stood with the knees
flexed to 53° (SD ± 10°). During SWBV, participants stood
with the knees flexed to 44° (SD ± 14°).
Sample size and data analysis
Sample size with power computations were described
previously [7,8]. In brief, sample size needed (based on
paired t-test with α = 0.05, β = 0.90, and n = 14) was
n = 16 for the 5-chair test and n < 10 for the TUG test.
A sample of 16 participants was required based on the
simulated ADL dependent variables. After normality
was confirmed [15,16] repeated measures analysis of
variance with repeated contrasts were computed for
acute and long-term data for both WBV and SWBV
with the Statistical Package for Social Scientists (SPSS
Version 19.0, Chicago IL™). Effect size was described
as Partial eta-squared (Partial η2). For long-term func-
tional performance results, significance was accepted
at p ≤ 0.05. To minimize potential of familywise error
rate of long-term gait results, significance was accepted
at p ≤ 0.02.
Results
A total of 15 participants with GOLD Stage II COPD
and one participant with GOLD Stage III COPD were
recruited to the trial with 100% compliance to the both
interventions (Figure 1). Demographic and disease char-
acteristics are presented in Table 1. Acute and long-term
results are shown in Table 2.
There was no acute effect of WBV or SWBV on rating
of perceived dyspnea and oxygen saturation (p > 0.05)
(Table 1). The WBV intervention increased heart rate by
as much as 12 beats.min−1 (p ≤ 0.05). The SWBV inter-
vention increased heart rate by as much as 7 beats.min−1
(p > 0.05).
Whole-body vibration improved performance of the
TUG (13%) and 5-chair tests (18%) (p = 0.01). Across the
first three weeks of WBV, TUG improvement was
0.5 sec (Partial η2 = 0.28, power = 0.99) and then an add-
itional 0.9 sec (Partial η2 = 0.41, power = 0.95) after six
weeks. Whole-body vibration also improved performance
of the 5-chair test after three weeks by 2.1 sec (Partial
η2 = 0.50, power = 0.95) and at Week 6 by 1.4 sec(Partial η2 = 0.49, power = 0.94). There was no effect of
SWBV on simulated ADLs (p > 0.33). Performance was
within ± 0.2 sec for both the TUG (2%) and 5-chair
(1%) tests. Kinematic variables of gait improved after
WBV (p = 0.01). Effect size was at least Partial η2 = 0.24
for stride length, Partial η2 = 0.14 for stride time, and
Partial η2 = 0.72 for stride velocity. There was no effect
of SWBV in kinematic variables of gait (p > 0.10).Discussion
The findings of this Phase II efficacy trial supported the
use of a standalone community-based WBV intervention
to improve functional performance of the lower limbs of
people with COPD while avoiding exacerbations of the
disease. Furthermore, WBV was more effective than
SWBV for improvement of functional performance, yet
comparable for acute markers of exercise tolerance. These
findings support our earlier proof-of-concept trial of
WBV as a mode of dyspnoea free physical activity [10].Exercise tolerance
Results of this trial compare favorably with other investi-
gations of resistance training and aerobic conditioning
of people with COPD. After 12-weeks of both training
modes, Borg CR-10 VAS values were not different within
and among resistance training and aerobic conditioning
for people with COPD [17]. However, during perform-
ance of the six-minute walk test, perceived dyspnoea
increased to a value of ‘6’ [17]. Concurrently, oxygen sat-
uration reduced from 95 to 87% [17] and has reduced to
similar values across other exercise investigations of
people with COPD [18,19]. The effect of WBV in this
trial was within the > 4% drop in oxygen saturation used
to define hypoxemia [18].
For people with mild to moderate COPD, long-term
physical activity can positively affect metabolic processes
through improved oxygen saturation [20]. For partici-
pants of this trial however, there was an absence of
meaningful change in dyspnoea and oxygen saturation
across the WBV intervention. As such, if metabolic pro-
cesses of people with COPD increased due to WBV, the
change was not represented with the Borg CR-10 VAS
and SpO2. Metabolic activity however, was shown to
increase as demonstrated by increased heart rate in this
trial. Across the trial, heart rate increased more during
WBV than during SWBV. Others have reported similar
increases in heart rate during WBV for sub-optimal
health [21] and healthy older adults [22]. Given the
known and broad physiological responses of the human
body to physical activity, WBV may be viewed as an
effective mode to increase metabolic activity of people
with COPD.
Figure 1 Flow of participation in the trial.
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Improvements in performance of the TUG test (13%)
and 5-chair test (18%) after WBV for people with COPD
in this trial were greater than the respective 6% and 12%
improvements reported after a two-month WBV inter-
vention of healthy older adults [23]. Given the commu-
nity dwelling sub-optimal health status of participants in
this trial, it is likely that the potential for improvement
in performance of ADLs in people with COPD after
WBV would be larger.A three-week resistance training combined with WBV
intervention for people with COPD reduced time taken
to complete the 5-chair test by 4.0 sec [5]. Results of this
efficacy trial show a 3.4 sec reduction of performance of
the 5-chair test after a six-week standalone WBV inter-
vention. For people with COPD, chair stands in 60 sec-
onds and stair climbing have improved after resistance
training and aerobic conditioning [24-26]. Compared
with resistance training, WBV is not as effective for
people with COPD because improvement of TUG test
Table 1 Demographic and disease characteristics of the
participants with COPD
Descriptor Mean SD
Age (years) 72 7
Stature (m) 1.71 0.1
Mass (kg) 85.7 20.4
BMI (kg.m-2) 29.3 6.1
SBP (mmHg) 139 13
DBP (mmHg) 75 10
Resting HR (beats.min-1) 82 10
FEV1 (L BTPS) 1.7 0.7
FEV1 % predicted 58.5 19.0
FVC (L BTPS) 3.0 0.8
FVC % predicted 83.2 15.0
FER % 52.3 10.8
PEF (L.sec-1) 4.2 0.8
N = 16 (4 females, 12 males). BMI: body mass index. SBP: systolic blood
pressure. DBP: diastolic blood pressure. HR: heart rate. FEV1: forced expired
volume of oxygen in the first second. FVC: forced vital capacity of the lungs.
FER: forced expiratory ratio (FEV1.FVC-1). PEF: peak expiratory flow. L BTPS:
Litres Body Temperature Pressure Saturated. Pack years range was 10.5 to 140
pack years.
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ing [27] compared with 13% in this trial. However, to
achieve such large improvements, the resistance training
intervention required supervision and equipment not
usually available in the home.
Gait
Previously, WBV with pulmonary rehabilitation [5] and
as a standalone out-patient intervention [6] improved
performance of the six-minute walk test. Participants in
this trial walked with longer strides, in a faster time after
the WBV intervention which may support previous find-
ings. Similarly, eight weeks of combined resistance train-
ing and WBV in healthy older adults lengthened step
length from 61 cm to 65 cm (7%) [28]. Stride length ofTable 2 Acute and long-term results
WBV
Baseline Week 3 Wee
Borg CR-10 VAS 1(1) 2(2) 2(1) 1(1) 1(1)
HR (beats min-1) 82(10) 92(10)* 86(11) 94(12)* 83(11)
SpO2 (%) 97(2) 96(2) 96(2) 96(2) 95(2)
TUG (sec) 11.3 (1.9) 10.7(1.7)* 9.8(1.9)*
5-chair (sec) 18.5(3.4) 16.4(2.7)* 15.1(2.4)*
SL (m) 1.14(0.16) 1.19(0.17)+ 1.27(0.11)+
ST (sec) 1.11(0.13) 1.09(0.12)+ 1.10(0.06)+
SVel (m.sec-1) 1.04(0.15) 1.10(0.15)+ 1.16(0.11)+
Results are mean (SD). Pre: pre bout. During: during the bout. HR: heart rate. SpO2:
SL: stride length. ST: stride time. SVel: stride velocity. *p ≤ 0.05. + p ≤ 0.02.participants in this trial was 13 cm longer (11%), which
is similar to the ≥ 14 cm improvement of healthy older
adults after resistance training interventions [29,30].
Similar effects were reported for gait velocity after resist-
ance training and aerobic conditioning for people with
COPD. Specifically, velocity increased 13%, from 0.89 m.
sec−1 to 1.01 m.sec−1 [25]. The 12% increase of stride
velocity for people with COPD in this trial is similar to
previous results in the range of 14 to 30% [24,27,31] for
people with COPD. For healthy older adults, a 12% im-
provement in gait velocity after resistance training was
described as an attractive strategy to improve gait [29].
When compared with this trial, WBV may also be an at-
tractive strategy to improve gait for people with COPD.
Given the known physiological benefits of aerobic con-
ditioning and resistance training on people with COPD
(e.g., skeletal muscle hypertrophy and increased oxida-
tive capacity), it may be appropriate to view possible
mechanisms of improvement in functional performance
of people with COPD after this trial with a similar per-
spective. However, given the predominance of Type II
muscle fibre activity during exercise for people with
COPD leading to increased anaerobic fatigue [32], it
may be possible that improvement of functional per-
formance of people with COPD after WBV could be
partly attributed to training of Type II skeletal muscle
fibres rather than for example, an increase of oxidative
capacity at the muscle. Given the known leg fatigue
exhibited by people with COPD due to high-intensity
exercise designed to improve anaerobic performance,
and persistence of poor exercise compliance associated
with symptom limited participation [3,33], WBV may
initially be a more attractive mode of exercise training
for people with COPD.
Compliance and drop-out
All participants successfully completed all WBV and
SWBV sessions however, the number of participants
reduced over the 14-week duration of this trial. ThePWBV
k 6 Week 9 Week 11 Week 14
2(1) 2(1) 2(2) 2(1) 2(1) 2(1) 2(1)
95(9)* 81(13) 88(13) 83(10) 88(13) 83(11) 90(8)






oxygen saturation. TUG: timed-up-and-go test. %-chair: 5-chair stands test.
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beyond the demands of the research during the washout
period (Figure 1). As the importance of compliance to
pulmonary rehabilitation had been documented and
problematic, it was meaningful that participants com-
plied 100% of the WBV intervention. As a mode of
exercise training to maintain exercise tolerance, avoid
exacerbations of COPD, and improve functional per-
formance of the lower limbs, efficacy of this WBV
intervention can be confirmed. Compared with other
interventions, the 100% compliance in this trial was
unique. The drop-out rate of three month resistance
training research projects ranged from 20% to 38%
[34,35]. Compliance, in some instances among healthy
adults was at best 79% [36] and as low as 75% [34] for
resistance training interventions. Symptom limitation
was a major reason for poor compliance among people
with COPD during pulmonary rehabilitation [3]. Given
that only 48% of older Australians are physically active
[37], the need of such activity that does not exacerbate
people living with sub-optimal health is salient. The re-
sults of the community-based WBV intervention used in
this trial confirm the ease and convenience of WBV
highlighted by maximum compliance and an absence of
drop-out during the WBV intervention. Compliance
however, may have occurred due to the supervised
nature of both the WBV and SWBV interventions.
Because physical activity in the home is typically
unsupervised, future randomised controlled trials of
WBV and long-term unsupervised habitual sustain-
ability should be conducted of people with COPD.
Limitations
This trial was limited as participant; (1) nutrition, exer-
cise history, motivation, and other environmental sup-
port mechanisms, and (2) current or past pharmacologic
treatment for COPD (with the exception of corticoste-
roids) were not profiled. Furthermore, and similar with
some resistance training interventions, the practical ap-
plicability of WBV as a standalone mode of exercise train-
ing in community-settings needs to be considered as the
cost of a vibration platform may limit accessibility.
It may be that the participants reached a ‘ceiling’ that
limited further improvement during SWBV and there-
fore, a placebo effect may have been systemic to the
WBV intervention. It may also be that; (1) simply stand-
ing on the prototype vibration platform with the knees
flexed was enough stimulus to maintain improvements
after WBV, or (2) participants were more physically ac-
tive after the WBV intervention despite the request not
to begin any new mode of physical activity during the
14-week trial. Future research should focus about rando-
mised controlled trials to more thoroughly describe
effects of WBV and a potential placebo affecting peoplewith COPD and describe the economic feasibility and
long-term exacerbations of standalone community-based
WBV interventions.
Conclusions
This was the first trial to quantify and describe benefits
of a standalone WBV intervention on exercise tolerance
and functional performance of the lower limbs of people
with COPD in a community-setting. Both the WBV and
SWBV interventions were conducted in the home of
each participant, which maximised participant compli-
ance to each intervention. Results of this Phase II trial
confirm efficacy of a WBV intervention to improve func-
tional performance of the lower limbs of people with
COPD. Whole-body vibration was a well-tolerated mode
of exercise training for people with COPD highlighted
by the absence of exacerbations of COPD.
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